For sales

Highlights from the Week of 27th April 2026 – 4th May 2026 in the world of pharma and healthcare!

Highlights from the Week of 27th April 2026 - 4th May 2026 ( FDA, Approval ) AstraZeneca's fixed-dose triple-combination therapy, BREZTRI AEROSPHERE, gains FDA approval for the maintenance treatment of asthma in patients aged 12 and older ( FDA, Approval ) Arvinas' VEPPANU receives FDA approval as the first-ever PROTAC therapy for the treatment of adults with ER+ or HER2- or ESR1 mutated, advanced or metastatic breast cancer ( FDA, Approval ) FDA approves Incyte's JAKAFI XR extended-release tablets to treat adults with intermediate- or high-risk myelofibrosis, polycythemia vera and adults or children who are 12 years and older with GVHD ( FDA, Approval ) Axsome secures approval from the FDA for its AUVELITY, targeting NMDA and sigma-1 receptors to treat dementia due to Alzheimer's disease Pg 1/3 All logos and trademarks remain the intellectual properties of their respective owners
Download

Connect with us

Please fill in the information below, and we'll get back to you.